|BioPontis Alliance for Rare Diseases||Co-Founder and Chair of the Board||Belgique|
Innovation in life sciences, biotechnology, rare diseases and orphan medicines, personalized Healthcare, public health policies, translational medicine, biobanking
Specialties: Orphan medicines, personalized healthcare, rare disease policies, technology transfer, biobanks
– Aujourd’hui (2 ans 6 mois)Raleigh, USA & Brussels, Belgium
BioPontis Alliance for Rare Diseases is a unique international non-profit organization bridging the gap between academic and commercial stage development of therapies for rare diseases. The organization has two independent legal entities, one in the USA and one in Europe, governed by the same Board and management. It is dedicated to translational research on therapies for rare diseases of the human brain and nervous system. Most of these rare diseases are caused by faulty genes. Less than 5% of the 7-8000 known rare diseases have a treatment. BioPontis Alliance for rare diseases is the first non-profit organization designed specifically to translate discovery science into candidate new therapies for these diseases. The first program of BioPontis on Charcot-Marie-Tooth disease.
– Aujourd’hui (5 ans 11 mois)Oud-Heverlee, Belgium
Consultancy projects in innovation, patient relations, rare diseases/orphan drugs, translational medicine and personalized healthcare.
– Aujourd’hui (10 ans 5 mois)Brussels, Belgium
KVAB is the Academy for Sciences and Arts for Flanders, Belgium.
I am an elected member of the group of applied sciences (KTW) since 2006. I am also elected as Flemish Thinker 2015 and have organized in that context an international symposium on Innovative Entrepreneurship via Spin-Offs of Knowledge Centres in Brussels on June 10th 2015
– (1 an 9 mois)Heverlee, Belgium
Translation medicine and biobanking project with all universities and university hospitals of the region of Flanders, Belgium, together with the biopharma industry and the government.
– (2 ans)Heverlee, Belgium
CMI is a non-profit organization which works with all universities and university hospitals in Flanders, Belgium on translational biomedical research using focused, high quality biobanks of human biological material.
– (7 ans)Stockholm, Sweden
ICORD is a non-profit foundation working on international policies for rare diseases and orphan drugs. It organizes the International Conference for Orphan Drugs and Rare Diseases. The 6th ICORD conference took place in Buenos Aires, Argentina. The 7th was in Tokyo, Japan in the beginning of 2012. Next conference will be in November 2013 in St-Petersburg, Russia.
– (19 ans 4 mois)Europe and International
– In 1992, Erik joined Genzyme as Vice-President Diagnostics and Genetics, Europe
– He was instrumental in setting up Genzyme’s activities and structure in Europe and has been a Board member of many Genzyme affiliates in Europe, and a member of Genzyme’s European Management Board.
– From 1996, he set up the European public affairs and health policy functions for for Genzyme working on policies related to healthcare systems and sustainability, rare diseases and orphan medicines, genetic testing, advanced therapies and personalized medicine, as well as coordinating Genzyme’s corporate communications in Europe.
– In 1997, he was a member of the EC/JRC-IPTS Futures group on healthcare (Sevilla, Spain), and proposed Europe to work on policies for cell therapy and human medical genetic testing, later turning into the ATMP Regulation and the project EuroGenTest
– In 2008-2010 he was a member of the Relative Effectiveness and pricing and reimbursement working group of the High Level Pharmaceutical Forum in the EU .
– Erik represented industry in the National management committee for Rare Diseases and Orphan Medicines, operating as a Fund within the King Baudouin Foundation.
– He chaired the Pharma.be/Bio.be industry rare diseases and orphan drugs task force in Belgium.
– (17 ans 2 mois)Brussels, Belgium
– EPPOSI is set up as a platform for consensus building on European public health policy issues, between patients’ organizations, scientific organisations and industry and working with health authorities in Europe and the member states.
– EPPOSI is a non-profit organization working with European and national authorities on public health
– EPPOSI is a think tank on serious and complex public health issues in Europe
– (1 an 8 mois)Heverlee, Belgium
Having been a member of the strategic council proposing the creation of the Center for Medical Innovation CMI, I became a founding member of the management Board after its founding.
– (15 ans)Brussels, Belgium
– Erik is a founding Board member of EuropaBio, the European Association for Bioindustries as well as a past Chair of its Main Board and of its Healthcare Council.
– Erik received the first EuropaBio Award of Merit
– In 1997, he was the founder of EuropaBio’s Ethics Working Group, which published industry’s first Core Ethical Values in the biotech field (1998 and reviewed in 2010).
– He founded (in 1998) and chaired the European Industry’s Rare Diseases and Orphan Medicines working group, a joint joint EBE/EFPIA-EuropaBio Task Force , until 2011
– Erik represented EuropaBio in the High Level Pharmaceutical Forum’s Relative Effectiveness and Pricing and Reimbursement Working Groups between 2007 and 2009.
– (7 ans 4 mois)Ghent and Antwerp, Belgium
In 1985, Erik wrote the business plan, discussed funding and co-founded the healthcare biotechnology company Innogenetics NV, one of the first biotech companies on healthcare in Europe. He was its General Manager till 1992.
Erik work previously at INNOVI NV, Brussels, Belgium, a technology management company set up by the Flemish government and major industries from Flanders to promote innovation and technology transfer into new companies. INNOVI was involved in Flanders Technology International and the set-up of innovation days in 1983-1985.
– (2 ans 1 mois)Région de Bruxelles, Belgique
Advisor to the Cabinet of the Minister-President of Flanders on biotechnology and life sciences.
– (5 ans 10 mois)Europe out of Brussels, Belgium
– After having been Quality Coordinator at the largest clinical laboratory of Belgium at Leuven University’s Academic Hospital, Erik started his professional career in 1977 at Baxter Healthcare as European product manager for the AMINCO division, selling sophisticated research and clinical laboratory equipment in Europe, and as Software specialist Europe
– In 1979, he worked for the Hyland Diagnostics division, as Marketing and Production manager for a series of clinical laboratory products and related equipment .